ArticleIntestinal research2018
High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India.
Article in Intestinal research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Regional risk ofFrontiers in pharmacology · 2023Pooled it
- Trends in the use of biologic agents and their persistence rates in inflammatory bowel disease in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study.World journal of gastroenterology · 2026Article
- Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: is the risk still too great? A case report.Journal of surgical case reports · 2025Article
- Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs.Therapeutic advances in gastroenterology · 2025Review
- Bronchoesophageal fistula in a patient with Crohn's disease receiving anti-tumor necrosis factor therapy.Clinical endoscopy · 2023Article
- Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Article
- Tumor necrosis factor-alpha antibody labeled-polyethylene glycol-coated nanoparticles: A mesenchymal stem cells-based drug delivery system in the rat model of cisplatin-induced nephrotoxicity.Veterinary world · 2022Article
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010-2017.Open forum infectious diseases · 2022Article
- Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.BMC gastroenterology · 2021Article
- Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn's disease.Intestinal research · 2021Article
- Long-term outcomes of anti-tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Vedolizumab in Inflammatory Bowel Disease: West versus East.Inflammatory intestinal diseases · 2021Review
- Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.International journal of inflammation · 2021Review
- Article
- Long-term outcomes in perianal fistulizing Crohn's disease in a resource-limited setting: A cohort analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.Journal of nanobiotechnology · 2020Article
- Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.
methodsThis retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated).
resultsOf 69 patients (22 ulcerative colitis/47 Crohn's disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5-48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0-84.5 weeks) of IFX. Of these 8 patients' none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn's disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation.
conclusionsThere is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.